Article
A pharmacogenetic predictive model for paclitaxel clearance based on the DMET platform.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Sept 2013
de Graan Anne-Joy M, Elens Laure, Smid Marcel, Martens John W, Sparreboom Alex, Nieuweboer Annemieke J M, Friberg Lena E, Elbouazzaoui Samira, Wiemer Erik A C, van der Holt Bronno, Verweij Jaap, van Schaik Ron H N, Mathijssen Ron H J
Abstract excerpt
PURPOSE: Paclitaxel is used in the treatment of solid tumors and displays high interindividual variation in exposure. Low paclitaxel clearance could lead to increased toxicity during treatment. We present a genetic prediction model identifying patients with low paclitaxel clearance, based on the drug-metabolizing enzyme and transporter (DMET)-platform, capable of detecting 1,936 genetic variants in 225...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.